anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Approximately 10% of submucosal invasive (T1) colorectal cancers demonstrate extraintestinal lymph node metastasis, necessitating surgical intervention with lymph node dissection. The ability to identify T1b (submucosal invasion depth ≥ 1000 µm) as a risk factor for lymph node metastasis via pre-treatment endoscopy is crucial in guiding treatment strategies. Accurately distinguishing T1b from T1a (submucosal invasion depth < 1000 µm) or dysplasia remains a significant challenge for artificial intelligence (AI) systems, which require high and consistent diagnostic capabilities. Moreover, as endoscopic therapies like endoscopic full-thickness resection and endoscopic intermuscular dissection evolve, and the focus on reducing unnecessary surgeries intensifies, the initial management of T1 colorectal cancers via endoscopic treatment is anticipated to increase. Consequently, the development of highly accurate and reliable AI systems is essential, not only for pre-treatment depth assessment but also for post-treatment risk stratification of lymph node metastasis. While such AI diagnostic systems are still under development, significant advancements are expected in the near future to improve decision-making in T1 colorectal cancer management.
The invention belongs to the technical field of biological medicine, and particularly relates to albumin HSA-hydrohobic-IIB with self-assembly performance and application thereof. The amino acid sequence of the albumin is shown as SEQ ID No. 1. The albumin can be self-assembled to form nanoparticles, and the obtained nanoparticles have uniform morphology and average particle size of 115.4nm. Cell experiments show that the albumin has good biocompatibility. The drug release experiment shows that the nano-micelle of the albumin has obvious drug release effect.
A method of reducing the risk associated with administering adenoviral particles to subjects undergoing adenoviral gene therapy. An extremely low titer of adenovirus neutralizing antibodies is believed to lead to an acute virus-mediated cytotoxicity. Neutralizing antibodies prevent the hepatotoxic effects of adenoviruses administered by way of the hepatic artery. An improved adenoviral gene therapy method of the type involving the administration, at a certain point in time, of recombinant adenoviruses containing a gene of interest to a subject wherein the improvement includes, before administering the recombinant adenovirus containing the gene of interest, providing the subject with neutralizing antibodies directed to the recombinant adenovirus. In one aspect of the method, the subject is provided with the antibodies by administering to the subject adenovirus of the same type as the recombinant adenovirus to be administered, at a before the administration of the recombinant adenovirus, to induce in the subject an immune response against the adenovirus. Alternatively, when insufficient time exists, or the subject is immunocompromised, the subject is directly provided with the neutralizing antibodies by administering, to the subject, antibodies directed against the same serotype of adenovirus as the recombinant adenovirus or antibodies cross-reactive with the serotype of the recombinant adenovirus. In such a case, the antibodies are administered about one hour before the administration of the recombinant adenovirus containing the gene of interest. In this aspect of the invention, human antibodies or humanized antibodies are particularly preferred to be administered parenterally to the subject.
This is a phase 1, non-randomized, single-arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant (HCT). Such a trial is a necessary step prior to an evaluation of efficacy, as pirfenidone is known to be associated with adverse events (AEs) of the liver, gastrointestinal system and skin, organs frequently affected in GVHD. Approximately 30 patients will be enrolled, all patients will follow the same drug titration approach. The primary endpoint will be drug tolerability as measured by: the number of patients that are able to maintain the recommended dose of pirfenidone (2403 mg/d) without dose reduction lasting more than 21 days, due to adverse events (AEs). Changes from Baseline to Week 52 will be studied using validated health-related quality of life scales. Eligible patients aged \> 18 years must have a diagnosis of BOS according to pre-specified criteria. Patients will be required to have an %FEV1 or %FVC decline \>20% from pre-transplant baseline and symptoms of dyspnea, or cough. Eligible patients will enter the Screening Period, which may last up to 28 days. The dose of pirfenidone will be titrated over 3-8 weeks. Patients will have a telephone assessment at Week 1 and 2. An in-clinic assessment will occur every 1-3 months as part of their usual clinical care in the Stanford University Lung GVHD clinic. Patients will complete an AE and dosing compliance diary. If patients discontinue study treatment early for any reason, they will continue with all scheduled study procedures through Week 52. All deaths will be reviewed by a Mortality Assessment Committee (MAC). An external Data Safety Monitoring Board (DSMB) will monitor patient safety during the study.
Only generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis.
There is evidently great potential in implementing workplace health promotion programs, but more randomized trials are needed to determine which interventions are worksite-effective in helping to decrease inactive behaviors and increase engagement in healthy lifestyle activities. For employers, it could mean improving the health and productivity of employees. For workers, especially those in physically and/or psychologically demanding positions, it could mean developing strength, muscular endurance and agility to reduce musculoskeletal pain while developing the stress reduction skills that reduce long-term sickness and absenteeism risks. While changing behavior in a complex workplace is, as seen in multiple studies, difficult due to the need to change workplace and organizational culture between employers and employees, this study aims to identify the effectiveness of workplace interventions in relation to counseling for university employees to increase overall work fitness without affecting any hierarchal interactions at the work site. Simply put, the investigators will examine the benefits of a workplace exercise and mindfulness (two-prong) intervention (in combination) vs. a group who just receive a workplace exercise intervention. Both interventions will be guided by health coaches. Given the limited research with health coaching and workplace interventions for university workers, the aim is to contribute to a developing research literature. This study is geared to engage university employees at their workplace over a 3 month period. Participants will be assessed through pre and post physical and psychological measures and will also undergo semi-structured interviews (SSI). The investigators hypothesize that making available these various fitness and well-being programs for university employees will effectively improve their overall fitness (peak VO2) and psychological health (stress, depression, anxiety, work satisfaction), making them more efficient, positive and work-productive. Specifically, the investigators hypothesize that the exercise and mindfulness meditation group will demonstrate significant improvements when compared to the group solely receiving exercise-oriented health coaching. Improvements will be seen across all measures of physical (such as VO2 peak and BMI) and psychological (such as depression, stress, anxiety, work-life balance) function and will be sustained at 3 month follow-up, indicating a more effective means of initiating fitness at the workplace
Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
TAK-988 tablet or TAK-988 placebo-matching tablet, orally, once on Day 1, followed by a washout period of 2 days and twice daily (6- hour interval) on Day 3 and continue to Day 17 to healthy Japanese participants. Dose will be determined based on previous MRD cohorts.
YF476 is clearly a potent and selective gastrin/CCK-B antagonist and should inhibit basal and meal-stimulated gastric acid secretion and enhance gastric emptying of a liquid meal in man. Therefore YF476 might benefit patients with reflux oesophagitis. The compound has been well tolerated in animal toxicity studies at doses in excess of the projected therapeutic dose in patients, and merits studies in healthy volunteers. Extrapolation from data obtained in animals suggests that a single oral dose of about 10mg of YF476 should compare favourably with an oral dose of 150mg of ranitidine in man with respect to effect on basal and food-stimulated gastric acid secretion. Therefore in the proposed study a range of doses of YF476 encompassing that dose will be studied; the exact dose of YF476 will be chosen on the basis of the previous study but the top dose will not exceed 100mg. 24-hour ambulatory gastric pH will be monitored via an intragastric pH electrode (7-10). Although there is variability between subjects with respect to the effects of food and drug treatment on gastric pH, the methodology for measurement of ambulatory gastric pH is robust.
Patients will undergo a virtual reality and olfactory stimuli therapy session at their appointment where they receive their pulmonary function test, 90 minutes before surgery, and each day they recover in the hospital. In addition, patients will receive nighttime olfactory stimulation using a bedside olfaction device.
PROBLEM TO BE SOLVED: To prevent a materials that composes a blank of an artificial tooth from changing by processing and use or changing with time and to maintain its original shape and volume by forming the blank out of a plastic reinforced with glass fibers. SOLUTION: The blank 10 is made from a plastic material 12 of partly aromatic polyamide that is reinforced by fragments of cast glass fiber 14. The plastic material 12 consists of the glass fiber 14 that are aligned or not aligned according to the demand for each artificial tooth by a special method for casting production. The blank 10 can gain modulus of elasticity in tension of 22 GPa and Brinell hardness of 280 Mpa. Its breaking load is about 1,150 N without being added by an addition. It is right as its specific gravity is about 1.7 g per cubic cm. Moreover, as it is a bad conductor for heat, clients' dissatisfaction caused by heat conduction would not be occurred. Also, from the viewpoint of aesthetic, it has the semi-translucent color like tooth enamel and it can be transmitted by lights.
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL.
A fluid delivery device for transdermal delivery of a fluid to a patient. The device comprises an envelope that may be applied to a patient’s skin. The envelope comprises at least one diffusion layer (20) coupled to at least one impermeable layer (18) such that at least a chamber (22) is defined therebetween. Other embodiments include internal diffusion layers (42), and thus possess additional chambers, as well. In one arrangement, a boundary layer (200) permits the device to be removably secured to a patient and inhibits radial migration of fluid beyond the periphery of the device. In another arrangement, preferably, an anti-microbial layer (330) is provided to inhibit the growth of microorganisms.
Objective Patients with acute myocardial infarction (AMI) often have peripheral artery disease (PAD). It is well known that the long-term clinical outcomes of AMI are worse in patients with a low ankle-brachial index (ABI) than in patients with a preserved ABI. Unlike ABI, the association between the inter-arm blood pressure difference (IABPD) and clinical outcomes in patients with AMI has not yet been established. This retrospective study examined whether or not the IABPD is associated with long-term clinical outcomes in patients with AMI. Methods We included 979 patients with AMI and divided them into a high-IABPD group (IABPD ≥10 mmHg, n=31) and a low-IABPD group (IABPD <10 mmHg, n=948) according to the IABPD measured during hospitalization for AMI. The primary endpoint was the all-cause mortality rate. Results During a median follow-up duration of 694 days (Q1, 296 days; Q3, 1,281 days), 82 all-cause deaths were observed. Kaplan-Meier curves showed that all-cause death was more frequently observed in the high-IABPD group than in the low-IABPD group (p<0.001). A multivariate Cox hazard analysis revealed that a high IABPD was significantly associated with all-cause death (hazard ratio 2.061, 95% confidence interval 1.012-4.197, p=0.046) after controlling for multiple confounding factors. Conclusion A high IABPD was significantly associated with long-term all-cause mortality in patients with AMI. Our results suggest the usefulness of the IABPD as a prognostic marker for patients with AMI.
Burn related pain and anxiety is an important health problem. Surgical procedures and physical rehabilitation is commonly associated with pain and anxiety among burn injuries. Burn pain initially associated with size and degree of burn followed by post rehabilitation procedures and infections. Pain during burn incident and expectation of pain in treatment procedures create severe anxiety in most of the patients. In this investigation researcher is going to use listening to an audio clip (piece of self-selected music, sound from nature, or religious recitations) as a non-pharmacological intervention. Audio pieces are used for clinical purposes as complementary and alternative medicine. Although it is not practiced extensively due to the lack of evidence-based results in this particular area of research. This is an open label Randomized controlled trial aimed to assess the effectiveness of listening to an audio clip as an adjunct to TAU among hospitalized burns patient.

This study is open label, prospective, parallel group, randomized control design. The trial compares thosepatients with intervention group and control group with treatment as usual. Based on the inclusion criteria those patients with 10-30% of burns and need to stay in hospital for 10 days and withpain score of \>=4 will be included in the study. The samples will be divided into two groups by randomly assigning the patients to each group. The analysis will be conducted to assess the effectiveness of listening to an audio clip for controlling pain and anxiety. No blinding or masking will be performed in this study.The patients in the intervention group will be introduced to the music player before and the procedure. After the preparation of the intervention subsequently on the same day or during the next day's prior to dressing NRS and BAI will be administered to evaluate the patient's pain and anxiety levels. After completion of intervention pain, anxiety and hemodynamic parameters will be collected. Treatment as usual will be provided for all control group patients as per Unit Protocol. The primary outcome was reduced pain and anxiety levels during the dressing changes as evidenced by reducing 15-20% in experimental group as compared to control group with treatment as usual.
Parlodel SnapTabs or capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), Parlodel therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing “end of dose failure’’ on levodopa therapy. Parlodel therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (“on-off” phenomenon). Continued efficacy of Parlodel therapy during treatment of more than 2 years has not been established.

Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson’s disease with Parlodel. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in Parlodel-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for Parlodel therapy.
This is a single-institute retrospective study comparing the efficacy of WeChat-based patient education and conventional patient education in the management of Helicobacter pylori eradication. We identified all patients aged between 18-75 years old and had been prescribed a 14-day course of bismuth-contained quadruple therapy for H. pylori infection in our outpatient clinics between 1 July 2019 and 31 July 2021. H. pylori infection was confirmed by any two positive outcomes of rapid urease test,13C-urea breath test (UBT) and histopathology. Patients who had H. pylori therapy history, using other therapeutic regimens or unwilling to take prescribed medications were excluded. Demographic data, treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved. The main indicator is eradication rate, as the secondary indicators are compliance and adverse events.
BACKGROUND: Mental health conditions such as depression, anxiety and post-traumatic stress disorder (PTSD) are being increasingly recognised as common adverse outcomes for critical illness survivors. These conditions can have lasting consequences on their wellbeing, ability to return to their pre-illness level of functioning and health-related quality of life. There is a paucity of South African data in terms of the psychological aspects of the post-intensive care unit (ICU) syndrome.
OBJECTIVE: To identify and characterise patients who suffered from significant symptoms of mental health disease and poor mental health- related quality of life after ICU admission and who may benefit from appropriate referral, further investigation and medical intervention.
METHODS: Critically ill patients in a multidisciplinary tertiary ICU were prospectively enrolled upon ICU discharge. Survivors were screened for anxiety, depression and post-traumatic stress syndrome at 6 weeks and 6 months after hospital discharge. The Hospital Anxiety and Depression Score (HADS) and the Impact Of Events Scale - Revised (IES-R) were used as screening tools. The mental component summary score (MCS) of the RAND short form-36 was used to determine the effect of psychological symptoms on health-related quality of life (HRQOL).
RESULTS: The median age of the 107 ICU survivors was 42 years, and half of them were admitted for complications of COVID-19. Six out of every 10 ICU survivors experienced significant symptoms of anxiety, depression and/or PTSD at follow-up. At the 6-month study visit, 4 out of every 10 patients were experiencing significant psychological symptoms. Those affected had a significantly lower mental HRQOL when compared with those who were unaffected. More than half of those affected had co-occurrence of psychological symptoms. Significant symptoms of anxiety were common, with 5 out of every 10 participants experiencing significant symptoms at either, or both, of the study visits. More than 3 out of 10 of affected patients' symptoms only occurred after the 6-week visit. Associations for significant psychological symptoms comprised female sex, younger age, a diagnosis of trauma and frightening memories of the ICU admission.
CONCLUSION: The burden of mental health disease in ICU survivors is substantial, affecting their HRQOL. Six out of 10 patients experienced symptoms of anxiety, depression and PTSD, and more than half of those affected experienced co-occurrence of the conditions. A third of those affected developed these symptoms only beyond 6 weeks after hospital discharge. A potentially modifiable association with psychological symptoms was frightening memories of the ICU stay.
PURPOSE: The clinical aspects and prognosis of eyes with endogenous endophthalmitis were compared over the last ten years. The occurrence and progression of endophthalmitis are linked to the systemic immune inflammation index (SII) and clinical features.
METHODS: The study comprised patients with endogenous endophthalmitis and 64 patients without endophthalmitis who were treated at Hebei Province Eye Hospital in the last ten years. According to the prognostic visual acuity, patients with endophthalmitis were split into two groups: Group A and Group B. Underlying disease (hypertension, diabetes, tuberculosis), infection risk (liver abscess, urinary tract infection, and recent abdominal surgery), signs and symptoms, and complete blood count were among the evaluation parameters (neutrophil count, lymphocyte count, monocyte count, platelet count, red blood cell distribution width). The NLR, PLR, MLR, and SII values were calculated. A nonparametric test was used to examine the clinical features and complete blood count results of patients in each group. To determine the parameters linked to endophthalmitis progression, researchers used principal component and ordinal logistic regression analyses.
RESULTS: The study comprised a total of 25 eyes and 22 individuals with endogenous endophthalmitis. Infectious bacteria included Staphylococcus aureus, Micrococcus luteus, Staphylococcus hemolyticus, and so on. The visual acuity of the affected eye ranged from 2.7 (1.55, 2.7) LogMAR to 1.22 (0.6, 2.7) LogMAR during the 6-month to 8-year follow-up period. The neutrophil, monocyte, and PLT counts, NLR, PLR, and SII values and other markers were considerably higher in Groups A and B than in the control group. The likelihood model of the SII and sex, age, onset time, diabetes, hypertension, monocyte count, and red blood cell distribution was the best, and its increase was strongly connected with the occurrence and progression of endophthalmitis, according to ordinal regression analysis.
CONCLUSION: Patients with endophthalmitis had significantly higher blood neutrophil, monocyte, and PLT counts and SII, NLR, PLR, and MLR values. The SII can be employed as a biomarker for predicting endophthalmitis severity and prognosis.
Patients who are routinely followed up will be included in the control group. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days.